期刊文献+

左旋卡尼汀、镁-极化液配伍治疗缺血性心脏病心力衰竭45例临床观察 被引量:1

Clinical observation of L-carnitine and Mg-GIK on 45 patients with ischemic heart disease and congestive heart failure
下载PDF
导出
摘要 目的 :评估左旋卡尼汀 ( L- CN)与镁 -极化液 ( Mg- GIK)配伍治疗缺血性心脏病( IHD)心力衰竭疗效和安全性。方法 :选择 IHD心力衰竭患者 90例 ,心功能 ( NYHA分级 ) ~ 级 ,随机分成两组 ,对照组给予硝酸酯类、利尿剂、洋地黄、β-受体阻滞剂、血管紧张素转换酶抑制剂、Mg- GIK等常规治疗 ;治疗组在常规治疗的基础上 ,每次给予 L- CN2 .0 g加入 Mg- GIK液中静滴 ,2~ 3h滴入 ,每天 1次 ,1 0 d为 1个疗程。结果 :治疗后心功能改善总有效率 :对照组为 66.7% ,治疗组为 91 .1 % ,两组相比有显著性差异 ( P<0 .0 1 )。心电图心肌缺血 ST- T改善总有效率 :对照组为 5 3.3% ,治疗组为 77.8% ,两组相比有显著性差异 ( P<0 .0 5 )。随访观察 3个月 ,对照组再入院率为 31 .1 % ,而治疗组仅为 8.9% ,两组相比有显著性差异 ( P<0 .0 5 ) ,两组病死率无明显差异 ( P>0 .0 5 )。两组均无药物不良反应。结论 :L-CN与 Mg- GIK配伍能有效改善 IHD心力衰竭患者心功能和心肌缺血 ,减少再入院率 。 Objective: To evaluate clinical effect of L-carnitine (L-CN) and Mg-GIK on patients with ischemic heart disease (IHD) and congestive heart failure. Mothods: 90 cases of IHD and congestive heart failure were randomly divided into the control group of normal treatment (Nitrates, diuretics, digitalis, βblocker, ACEI, Mg-GIK) and treatment group (normal treatment combined with L-CN). The treatment course was ten days. Results: The effective rate in improving heart function was 91.1% in treatment group and 66.7% in the control group after ten days (P<0.01). No adverse reactions related to the drug were observed. Conclusion: L-CN and Mg-GIK combined with normal treatment can improve heart function effectively when used to treat IHD and congestive heart failure.
出处 《陕西医学杂志》 CAS 北大核心 2004年第4期369-371,共3页 Shaanxi Medical Journal
关键词 左旋卡尼汀 镁-极化液 配伍 治疗 缺血性心脏病心力衰竭 临床观察 Coronary disease/complications Heart failure, congestive/diagnosis Heart failure, congestive/drug therapy Carnitine/therapeutic use Magnesium/therapeutic use
  • 相关文献

参考文献9

  • 1高峰,施东伟,王晓明,董玲,王跃民,马新亮.极化液对缺血/再灌大鼠心肌细胞死亡及心脏功能的影响:胰岛素的关键作用[J].中华内科杂志,2003,42(3):148-152. 被引量:37
  • 2陈妙茹 邓斌.左旋肉毒碱治疗冠心病心绞痛疗效观察.实用医学杂志,2000,16(2):183-185.
  • 3Loster H,Keller T,Grommisch J,et al. Effects of L-carnitine and its acetyl and propionyl on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 31P-NIMR spectroscopy. Mol Cell Biochem ,1999,200(2) : 93.
  • 4Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in conjestive heart failure secondary to dilated cardiomyopathy and to coronary,hypertensive and valvular heart diseases. Am J Cardiol, 1990,65(11) : 755.
  • 5Kobayashi A, Masumura Y, Yamazaki IV. L-carnitine treatment for congestive heart failure:experimental and clinical study. Japanese Circulation J,1992,56(1) : 86.
  • 6Apstein CS. Increased glycolytic substrate protection improves ischemic cardiae dysfunction and reduces.Am Heart J ,2000,139(2pt3) : 107.
  • 7Fath-Ordoubadi F, Beatt KJ. Glucose-insulinpottassium therapy for treatment of acute myocardial infarction; an overview of randomized placedbocontrolled trials. Circulation , 1997; 96 (4) : 1152.
  • 8Diaz R, Paolasso EA, Piegas LS, et al. On behalf of the ECLA (Estudios cardiologicos latin america ).collaborative group. Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulinpotassium pilot trial. Circulation, 1998,98 (21) ;2227.
  • 9Broomhead CJ,Colvin MP. Glucose, insulin and the cardiovascular stsytem. Heart, 2001,85 : 495.

共引文献40

同被引文献15

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部